S&P 500 Futures
(0.03%) 5 334.75 points
Dow Jones Futures
(0.03%) 40 050 points
Nasdaq Futures
(0.13%) 18 717 points
Oil
(-0.45%) $78.28
Gas
(-0.58%) $2.40
Gold
(-0.33%) $2 387.00
Silver
(0.04%) $29.74
Platinum
(1.31%) $1 084.10
USD/EUR
(0.16%) $0.920
USD/NOK
(0.34%) $10.70
USD/GBP
(0.11%) $0.789
USD/RUB
(0.22%) $90.89

FY/2023

Generated By Getagraph.com: 2023-12-31

Inventiva S.A. [IVA] 2.47% $ 3.74
取引所: NASDAQ セクター: Healthcare 産業: Biotechnology

Inventiva S.A. Reports Fiscal Year 2023 Financial Results

Inventiva S.A. (NASDAQ:IVA), a leading biotechnology company in the healthcare sector, presented its financial outcomes for the fiscal year ended December 31, 2023.

Financial Highlights

In a year marked by significant advancements in its lanifibranor development program, Inventiva reported substantial financial results:

Inventiva has demonstrated remarkable financial resilience, with a current market capitalization of €191.26 million and secured financing to support its ongoing operational activities and research initiatives.

Operational Update and Outlook

2023 was a pivotal year for Inventiva, marked by significant milestones and progress in its development programs:

Looking ahead, Inventiva remains committed to achieving its critical milestones for 2024, emphasizing the last patient, first visit for the Phase 3 NATiV3 clinical trial, targeted for the first half of the year. The company's optimism is mirrored in its strategic initiatives and robust data supporting lanifibranor's efficacy and safety profile.

Conclusion

In conclusion, Inventiva S.A. continues to exhibit strong financial and operational performance despite the inherent challenges in biotech R&D. The company is poised for significant advancements in the coming fiscal year, supported by a solid financial foundation, groundbreaking clinical results, and strategic partnerships. Inventiva's dedication to enhancing patient care through innovative therapies remains at the core of its operations, promising a brighter future for patients with NASH/NASH.

Revenues FY - 2023

Revenue Gross Profit Operating Expenses Interest Expense EBITDA Net Income EPS
€17.48M €17.50M €122.96M €5.18M €-105.48M €-110.43M €-2.43

Balance FY - 2023

Net IncomeDepreciation and AmortizationStock Based CompensationChange in Working CapitalNet Cash Provided by Operating ActivitiesCapital ExpenditureFree Cash Flow
€-110.43M€2.53M€3.97M€22.53M€-81.61M€-540 000€-82.15M

Other Reports

Symbol Period Year Title
BATL Q1 2024 Q1 2024 Financial Results: Battalion Oil Corp (AMEX: BATL)
PBH FY 2024 Prestige Consumer Healthcare Inc Q4 2024 Financial Results
CTM Q1 2024 CTM Q1 2024 Financial Results
XGN Q1 2024 Exagen, Inc. First Quarter 2024 Financial Report
CMGR Q1 2024 Clubhouse Media Group, Inc. Q1 2024 Financial Results
LEAT Q1 2024 Leatt Corporation Reports Q1 2024 Financial Results
HTBK Q1 2024 Heritage Commerce Corp Q1 2024 Financial Results
CTMX Q1 2024 Q1 2024 Financial Performance Analysis of CytomX Therapeutics Inc.
PGR Q1 2024 Q1 2024 Financial Results for Progressive Corp (PGR)
ZH FY 2023 Zhihu Inc. Full Year 2023 Financial Performance Review
ALLE Q1 2024 Allegion PLC Q1 2024 Financial Performance Report
NDAQ Q1 2024 Nasdaq Inc: Q1 2024 Financial Performance Overview
NBRWF Q1 2024 Q1 2024 Financial Results Analysis for Unspecified Company (Ticker: NBRWF)
EHC Q1 2024 Encompass Health Corp: Q1 2024 Financial Report Summary
STZ Q4 2024 Constellation Brands Inc Comprehensive Financial Report for Fiscal Year 2024
BFI FY 2023 BurgerFi International, Inc. Fiscal Year 2023 Fourth Quarter Financial Results
ASPI FY 2023 Annual Financial Report for Aspire Real Estate Investors, Inc. for Fiscal Year 2023
HTCR FY 2023 HeartCore Enterprises, Inc. - Fiscal Year 2023 Financial Performance Summary
IVA FY 2023 Inventiva S.A. Reports Fiscal Year 2023 Financial Results
REX Q4 2023 REX American Resources Corp Fiscal Year 2023 Financial Report
BAMR Q4 2023 BAMR Q4 2023 Financial Results Overview
KRNT FY 2023 Kornit Digital Ltd Q4 and Full-Year 2023 Financial Results
GPRK Q4 2023 GPRK Q4 - 2023
BRSYF FY 2023 BRSYF Report Full Year 2023
CAAS FY 2023 CAAS Report Full Year 2023
BAMR FY 2023 BAMR Report Full Year 2023
QNTO Q4 2023 Global Tech Solutions Inc. Financial Report FY 2022
BAMH Q4 2023 Tech Innovations Co. Annual Financial Report for the Year Ended December 31, 2022
BAM-WI Q4 2023 Comprehensive Annual Financial Report
BAM Q4 2023 Brookfield Asset Management Q4 2023 Financial Overview
SPGC FY 2023 Annual Financial Report - FY2023
VFF FY 2023 Village Farms International Reports Third Quarter 2023 Financial Results
SWIM Q4 2023 Latham Group Q4 and Full Year 2023 Financial Performance Report
YOU FY 2023 CLEAR Fiscal Fourth Quarter 2023 Financial Report Highlights
WRBY FY 2023 Warby Parker Fourth Quarter and Full Year 2023 Results
GLP FY 2023 Global Partners Fourth Quarter 2023 Financial Results
CAR FY 2023 Avis Budget Group, Inc. Comprehensive Financial Report for Fiscal Year 2023
CHRW FY 2023 C.H. Robinson Worldwide, Inc. Annual Financial Report for the Year Ended December 31, 2023
CARR Q4 2023 Carrier Global Corporation 2023 Financial Report
AYX Q4 2023 Alteryx, Inc. Annual Financial Report for Fiscal Year Ended December 31, 2023
AB Q4 2023 AllianceBernstein Holding L.P. Q4 2023 Financial Report
CCS FY 2023 Century Communities, Inc. Financial Report for the Year Ended December 31, 2023
SSD Q4 2023 Simpson Manufacturing Co., Inc. 2023 Financial Performance Overview
SKY Q3 2023 Skyline Champion Corporation Fiscal Q3 2024 Financial Summary
PTSI Q4 2023 PTSI Financial Report Q4 2023
PLTR Q4 2023 Palantir Technologies Inc. Financial Report for Q4 2023
KRC Q4 2023 No title found
IDXX Q4 2023 IDEXX Laboratories, Inc. - Q4 2023 Financial Report
GHM Q3 2023 GHM Financial Report 2023
NSC Q4 2023 North Southern Corporation Financial Report 2023